Cargando…

VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

Bevacizumab is used to treat metastatic colorectal cancer (mCRC). However, there are still no available predictors of clinical outcomes. We investigated selected single nucleotide polymorphisms (SNPs) in the genes involved in VEGF-dependent and -independent angiogenesis pathways and other major intr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papachristos, Apostolos, Kemos, Polychronis, Katsila, Theodora, Panoilia, Eirini, Patrinos, George P., Kalofonos, Haralabos, Sivolapenko, Gregory B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888109/ https://www.ncbi.nlm.nih.gov/pubmed/31752122 http://dx.doi.org/10.3390/ijms20225791

Ejemplares similares

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer
por: Papachristos, Apostolos, et al.
Publicado: (2020)

A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients
por: Panoilia, Eirini, et al.
Publicado: (2015)

Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review
por: Papachristos, Apostolos, et al.
Publicado: (2020)

Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment
por: Karatza, Eleni, et al.
Publicado: (2022)

Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer
por: Marisi, Giorgia, et al.
Publicado: (2023)

The Implications of Metabotypes for Rationalizing Therapeutics in Infants and Children
por: Katsila, Theodora, et al.
Publicado: (2015)

Whole genome sequencing in pharmacogenomics
por: Katsila, Theodora, et al.
Publicado: (2015)

Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow
por: Giannopoulou, Efstathia, et al.
Publicado: (2019)

Nutrigenomics: A controversy
por: Pavlidis, Cristiana, et al.
Publicado: (2015)

Pharmacometabolomics Informs Viromics toward Precision Medicine
por: Balasopoulou, Angeliki, et al.
Publicado: (2016)

Searching for Clinically Relevant Biomarkers in Geriatric Oncology
por: Katsila, Theodora, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2011)

The New Age of -omics in Urothelial Cancer – Re-wording Its Diagnosis and Treatment
por: Katsila, Theodora, et al.
Publicado: (2018)

Computational approaches in target identification and drug discovery
por: Katsila, Theodora, et al.
Publicado: (2016)

Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach
por: Karageorgos, Ioannis, et al.
Publicado: (2015)

Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
por: Papachristos, Apostolos, et al.
Publicado: (2023)

Characterization and Biological Evaluation of Propolis from Poland
por: Popova, Milena, et al.
Publicado: (2017)

ePGA: A Web-Based Information System for Translational Pharmacogenomics
por: Lakiotaki, Kleanthi, et al.
Publicado: (2016)

Exploring public genomics data for population pharmacogenomics
por: Lakiotaki, Kleanthi, et al.
Publicado: (2017)

Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection
por: Lanara, Zoi, et al.
Publicado: (2013)

Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia
por: Milosevic, Goran, et al.
Publicado: (2018)

Lack of association of the M129V polymorphism of the PRNP gene with pseudoexfoliation syndrome
por: Giannakopoulos, Marios P, et al.
Publicado: (2016)

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
por: Koutsoukos, Konstantinos, et al.
Publicado: (2017)

Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease
por: Katsila, Theodora, et al.
Publicado: (2016)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives
por: Dimitrakopoulos, Foteinos-Ioannis D., et al.
Publicado: (2020)

Expression of Syndecan-4 and Correlation with Metastatic Potential in Testicular Germ Cell Tumours
por: Labropoulou, Vassiliki T., et al.
Publicado: (2013)

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
por: Loupakis, Fotios, et al.
Publicado: (2013)

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
por: Krizova, Deli, et al.
Publicado: (2014)

Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer
por: Huang, Yuanyuan, et al.
Publicado: (2019)

Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway
por: Kawsar, Anusuya, et al.
Publicado: (2023)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
por: Chionh, Fiona, et al.
Publicado: (2022)

N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells
por: Feduska, Joseph M, et al.
Publicado: (2013)

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
por: Passardi, Alessandro, et al.
Publicado: (2016)

Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration
por: Papanastasiou, Anastasios D, et al.
Publicado: (2012)

Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration
por: Papanastasiou, Anastasios D., et al.
Publicado: (2018)

Iris Metastasis in a Patient With Small Cell Lung Cancer: A Case Report
por: Sakellakis, Minas, et al.
Publicado: (2016)

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
por: Ulivi, Paola, et al.
Publicado: (2015)

Deciphering next-generation pharmacogenomics: an information technology perspective
por: Potamias, George, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k2864dmpjdi7c0ualkhklor4ap